How did you know you relapsed? I'm worried about my symptoms
November 13, 2025
It's understandable to feel worried about starting treatment again after coming out of remission. BR (bendamustine and rituximab) is a combination therapy approach that pairs rituximab, a targeted therapy drug, with bendamustine, which is a chemotherapy medication.
Rituximab is considered a first-line treatment for SMZL Show Full Answer
It's understandable to feel worried about starting treatment again after coming out of remission. BR (bendamustine and rituximab) is a combination therapy approach that pairs rituximab, a targeted therapy drug, with bendamustine, which is a chemotherapy medication.
Rituximab is considered a first-line treatment for SMZL and often leads to fewer side effects than chemotherapy alone since it specifically targets B cells while largely leaving normal cells unaffected. For relapsed/refractory SMZL (when cancer returns or stops responding to previous treatments), there are several treatment options available. In addition to combination therapies like BR, newer treatments like BTK inhibitors are showing promise in improving outcomes for people with R/R SMZL.
Consider discussing any concerns about the BR treatment with your healthcare team. They can explain why they're recommending this specific approach and address any worries about side effects or effectiveness.
October 10, 2025
Join
Your Privacy Choices
